2021
Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer
MacNeil T, Vathiotis IA, Shafi S, Aung TN, Zugazagoitia J, Gruver AM, Driscoll K, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. Cancers 2021, 13: 5501. PMID: 34771664, PMCID: PMC8583434, DOI: 10.3390/cancers13215501.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesPancreatic ductal adenocarcinomaCancer-associated fibroblastsImmune checkpoint blockadePancreatic cancerCheckpoint blockadePDAC patientsTumor microenvironmentQuantitative immunofluorescenceExpression levelsProgression-free survivalLarge retrospective cohortMajority of patientsPotential prognostic valueLow tumor immunogenicityPotential clinical utilityDesmoplastic tumor microenvironmentImmunoinhibitory proteinOverall survivalRetrospective cohortIndependent predictorsImmunotherapy drugsPrognostic significancePrognostic valueTumor expressionCan a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?
Guo Y, Czeyda-Pommersheim F, Miccio JA, Mahalingam S, Cecchini M, Pahade J. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection? Abdominal Radiology 2021, 46: 5609-5617. PMID: 34557934, DOI: 10.1007/s00261-021-03284-5.Peer-Reviewed Original ResearchConceptsSubsequent R0 resectionOverall survivalR0 resectionNeoadjuvant therapyPancreatic ductal adenocarcinomaImaging responseMultivariable Cox proportional hazards analysisCox proportional hazards analysisPostoperative CA19-9Median overall survivalImproved diseaseProportional hazards analysisKaplan-Meier analysisSimilar diseasesPatient ageVascular involvementClinical stagingMethodsRetrospective analysisPredict SurvivalClinical parametersPDAC patientsCA 19CA19-9Mean ageCancer patients
2019
Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer
Xiao Y, Yang H, Lu J, Li D, Xu C, Risch HA. Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer. BMC Cancer 2019, 19: 1020. PMID: 31664937, PMCID: PMC6819453, DOI: 10.1186/s12885-019-6250-8.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaMetastatic pancreatic ductal adenocarcinomaOverall survivalSerum GGTSignificant dose-response associationCox proportional hazards modelMetastatic PDAC patientsDose-response associationMetastatic pancreatic cancerPancreatic cancer survivalSpecialized cancer hospitalBlood glucose levelsProportional hazards modelHazard ratioPrognostic roleCancer HospitalPDAC patientsCancer survivalSubgroup analysisPancreatic cancerDuctal adenocarcinomaMetastatic PCCancer occurrenceGlucose levelsMortality risk
2017
Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations.
Hu Z, Varghese A, Shia J, Zervoudakis A, Lowery M, Yu K, Chalasani S, Robson M, Stadler Z, Caron P, Kelsen D, Klimstra D, Kelly D, O'Reilly E. Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations. Journal Of Clinical Oncology 2017, 35: e15791-e15791. DOI: 10.1200/jco.2017.35.15_suppl.e15791.Peer-Reviewed Original ResearchMemorial Sloan Kettering Cancer CenterPancreatic ductal adenocarcinomaMismatch repair genesMismatch repair deficiencyMutational burdenGermline mutationsFollow-upTumor next generation sequencingNext generation sequencingSomatic mutationsPersonal/family history of cancerImmune oncology agentsResponse to immunotherapyCheckpoint inhibitor trialsLynch syndromePrognostically favorable subgroupHistory of cancerResectable diseaseUnresectable tumorsMismatch repairFavorable subgroupMSK-IMPACTInhibitor trialsPDAC patientsDuctal adenocarcinoma
2016
Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma
Poruk KE, Valero V, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Annals Of Surgery 2016, 264: 1073-1081. PMID: 26756760, PMCID: PMC4936958, DOI: 10.1097/sla.0000000000001600.Peer-Reviewed Original ResearchConceptsCytokeratin-positive CTCsPancreatic adenocarcinomaMesenchymal markersVimentin-positive CTCsEpithelial tumor cells (ISET) methodFourth leading causeBetter treatment stratificationPortal blood samplesSignificant independent predictorsPotential prognostic biomarkerBiology of metastasisDetection of CTCsSurgical resectionIndependent predictorsPrognostic factorsMedian timeMultivariable analysisPDAC patientsPrognostic utilityCancer deathPatient prognosisLeading causeTreatment stratificationCancer recurrencePoor survivalActivation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61
Sano M, Driscoll D, DeJesus-Monge W, Quattrochi B, Appleman V, Ou J, Zhu L, Yoshida N, Yamazaki S, Takayama T, Sugitani M, Nemoto N, Klimstra D, Lewis B. Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61. Neoplasia 2016, 18: 785-794. PMID: 27889647, PMCID: PMC5126137, DOI: 10.1016/j.neo.2016.11.004.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma developmentPancreatic cancer developmentWnt/b-catenin signaling pathwayB-cateninLSL-Kras<sup>G12D</sup>Premalignant pancreatic intraepithelial neoplasiaCancer developmentWnt/b-cateninUp-regulation of CYR61Pancreatic cancer cell linesSignaling pathwayPancreatic cancer modelHuman pancreatic ductal adenocarcinomaPancreatic intraepithelial neoplasiaActivation of Wnt signalingPancreatic cancer cellsPancreatic ductal adenocarcinoma cellsUp-regulatedIntraepithelial neoplasiaLSL-KrasCancer cell linesPoor prognosisPDAC patientsActivating mutations
2015
The Yale Gastrointestinal Cancer Biorepository: A comprehensive biospecimen and data resource for studying determinants of pancreatic ductal adenocarcinoma prognosis following curative-intent pancreaticoduodenectomy.
Gould Rothberg BE, Deminie C, Lazowski H, Gibson J, Cha C, Lacy J, Hochster H, Salem R. The Yale Gastrointestinal Cancer Biorepository: A comprehensive biospecimen and data resource for studying determinants of pancreatic ductal adenocarcinoma prognosis following curative-intent pancreaticoduodenectomy. Journal Of Clinical Oncology 2015, 33: 272-272. DOI: 10.1200/jco.2015.33.3_suppl.272.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaNeoadjuvant therapyCurative-intent pancreaticoduodenectomyDeterminants of outcomePancreatic ductal adenocarcinoma prognosisPDAC recurrenceMedical comorbiditiesIncident cancerSurgical resectionAdult patientsAdvanced cancerOncology clinicPDAC patientsVital statusGI cancersLifestyle factorsDuctal adenocarcinomaFamily historyPhysical activitySurgical pathologyPDAC prognosisTumor biologyBuffy coatCancerPatients
2012
Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts
He J, Edil BH, Cameron JL, Schulick RD, Hruban RH, Herman JM, Zheng L, Iacobuzio-Donahue C, Ahuja N, Pawlik TM, Wolfgang CL. Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts. Journal Of Gastrointestinal Surgery 2012, 17: 339-344. PMID: 23184271, PMCID: PMC3600849, DOI: 10.1007/s11605-012-2066-4.Peer-Reviewed Original ResearchConceptsCharlson-Age Comorbidity IndexOlder age groupsDate of surgeryYounger patientsOlder patientsAge groupsMedian agePDAC patientsPancreatic ductal adenocarcinoma patientsPatients Undergoing ResectionMedian overall survivalResectable pancreatic cancerLymph node positivityYoung patient cohortDuctal adenocarcinoma patientsYounger age groupsCurative resectionUndergoing resectionAbdominal painDistal pancreatectomyR0 resectionTotal pancreatectomyUnderwent pancreaticoduodenectomyElderly patientsNode positivity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply